Wordt geladen...

Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy

In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab, lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients. Two...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Biol Ther
Hoofdauteurs: Li, Bian, Tao, Wang, Shao-hua, Zhang, Ze-rui, Qu, Fu-quan, Jin, Fan, Li, Ze-fei, Jiang
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis 2018
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902233/
https://ncbi.nlm.nih.gov/pubmed/29333945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1414761
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!